2nd to market could certainly be an advantage but your product still has to be something hospitals want. Clearly ALF isn't going to be the answer to DaVinci. Also would like to know why the delay in FDA submission. CE for 6 years now and data from actual live patient surgery. What's the problem here?.....
Market Data 
Markets 
AI
